UBS keeps Myriad Genetics at neutral; price target cut
UBS maintains a neutral view on Myriad Genetics and cuts its price target to $3.60 per share from $6.00,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.